Resezioni polmonari maggiori con tecnica robotica in pazienti affetti da NSCLC: risultati oncologici a lungo termine

The aim of this study was to analyse the results of robotic lobectomy for lung cancer. Clinical records of 212 patients who underwent robotic major surgery from January 2010 to December 2015 for NSCLC were retrospectively analyzed; 127 male and 85 female. Mean age was 66,3 months (range 30 – 82). Surgical procedures consisted in 57 right upper lobectomy, 17 medium lobectomy, 74 right lower lobectomy, 34 left upper lobectomy, 29 left lower lobectomy and 1 superior bilobectomy. Mean operative time was 215 minutes (range 65 – 460), mean chest drainage duration was 3,6 days (range 2 – 13) and mean postoperative stay was 6,6 days (range 4 – 29). Mean disease free survival was 66,3 months (range 1 – 83). Disease free survival carcer-correlated was for adenocarcinoma 66,4 months (range 1 – 83), for squamous cell carcinoma 64,4 months (range 6 – 82) and for other histology was 47,6 months (range 6 – 58). Disease free survival stage-correlated for stage I was 75,6 months (range ); for stage II was 42,3 months (range 1 – 67); for stage III 51,2 months (range 19 – 74) for stage IV 10,3 months (range 0 – 12). Mean overall survival was 78,6 months (range 4 – 83). Overall survival carcer-correlated was for adenocarcinoma 79,2 months (range 4 – 83), for squamous cell carcinoma 79 months (range 12 – 82) and for other histology was 48,8 months (range 17 – 58). Overall survival stage-correlated for stage I was 82 months (range 9 – 83), for stage II was 73,5 months (range 10 – 82) for stage III was 61,4 months (range 22 – 68) and for stage IV 68 months. Robotic lung surgery is one of the most innovative and increasingly widespread techniques, due to to high-definition 3D vision and great maneuverability permit to perform pulmonary resection. The extended intuitive dexterity offered by the endo-wristed robotic instruments complemented by excellent magnified stereoscopic view, allows to perform a radical dissection, and the mini-invasive approach guarantees minimal injury to patients. This study suggests a positive oncological outcomes for patients NSCLC affected who underwent robotic major surgery